{
    "abstract": "Background: Invasive meningococcal disease has a high burden in young children, particularly during infancy. We investigated the immunogenicity and safety of a quadrivalent meningococcal conjugated vaccine (MenACWY-TT) co-administered with routine vaccines in healthy infants. Methods: In this phase IIIb study (NCT01340898) conducted in 2 centers in Lebanon and Mexico, 750 infants were randomized (2:1:1) to receive MenACWY-TT according to 3 schedules: 3+1 (at ages 2, 4, 6 and 15\u201318 months; group ACWY3+1); 1+1 (at 6 and 15\u201318 months; group ACWY1+1) or single-dose at 15\u201318 months (group ACWY1). All infants received PHiD-CV and DTPa-IPV/Hib at ages 2, 4, 6, 15\u201318 months. Immune responses to MenACWY-TT were assessed by rSBA and hSBA at 7 months (groups ACWY3+1, ACWY1+1) and pre- and post-vaccination at 15\u201318 months of age (all groups). Immune responses to co-administered vaccines, reactogenicity and safety were also evaluated. Results: Immunogenicity of MenACWY-TT at 1 month post-primary vaccination was demonstrated in group ACWY3+1: the lower limit of the 95% confidence interval for the percentage of infants with rSBA titers \u22658 was >80% for each serogroup. At 7 months of age, \u226593.9% of MenACWY-TT-primed infants had rSBA titers \u22658. Post-MenACWY-TT vaccination at age 15\u201318 months, \u226596.3% of participants in all groups had rSBA titers \u22658, regardless of the number of doses received previously. The percentage of infants with hSBA titers \u22654 were \u226587.2% and \u226589.7% at post-primary and booster/single-dose vaccination, respectively. Immune responses to PHiD-CV and DTPa-IPV/Hib did not seem impacted by co-administration with MenACWY-TT in infancy. The incidence of all adverse events was similar among groups. Serious adverse events were reported for 63/750 children in all groups; none were considered vaccine-related by investigators. Conclusion: Primary vaccination with 3 or 1 dose(s) of MenACWY-TT when co-administered with routine pediatric vaccines in infants is immunogenic and well-tolerated.",
    "author_highlights": [
        {
            "endOffset": 22450,
            "sentence": "Infants are at particular risk of meningococcal disease caused by Neisseria meningitidis.",
            "startOffset": 22361
        },
        {
            "endOffset": 22536,
            "sentence": "MenACWY-TT is a meningococcal vaccine targeting 4 of the 6 most prevalent serogroups.",
            "startOffset": 22451
        },
        {
            "endOffset": 22659,
            "sentence": "3+1 (at ages 2, 4, 6, 15\u201318 months); 1+1 (6, 15\u201318 months) or 1-dose (15\u201318 months) MenACWY-TT schedules were immunogenic.",
            "startOffset": 22537
        },
        {
            "endOffset": 22741,
            "sentence": "Co-administration of MenACWY-TT with other pediatric vaccines was well-tolerated.",
            "startOffset": 22660
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": {
            "authors": [
                {
                    "first": "Rabab Z.",
                    "initial": "R.Z.",
                    "last": "Jafri"
                },
                {
                    "first": "Asad",
                    "initial": "A.",
                    "last": "Ali"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Tevi-Benissan"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Durrheim"
                },
                {
                    "first": "Juhani",
                    "initial": "J.",
                    "last": "Eskola"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Fermon"
                },
                {
                    "first": "Keith P.",
                    "initial": "K.P.",
                    "last": "Klugman"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                },
                {
                    "first": "Samba",
                    "initial": "S.",
                    "last": "Sow"
                },
                {
                    "first": "Shao",
                    "initial": "S.",
                    "last": "Zhujun"
                },
                {
                    "first": "Zulfiqar A.",
                    "initial": "Z.A.",
                    "last": "Bhutta"
                },
                {
                    "first": "Jon",
                    "initial": "J.",
                    "last": "Abramson"
                }
            ],
            "doi": "10.1186/1478-7954-11-17",
            "issn": "14787954",
            "pub_year": 2013,
            "title": "Global epidemiology of invasive meningococcal disease",
            "volume": "11"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Stephen I.",
                    "initial": "S.I.",
                    "last": "Pelton"
                }
            ],
            "doi": "10.1016/j.jadohealth.2016.04.012",
            "firstpage": "S3",
            "issn": "1054139X",
            "lastpage": "S11",
            "pmid": "27449148",
            "pub_year": 2016,
            "title": "The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines",
            "volume": "59"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Whittaker"
                },
                {
                    "first": "Joana Gomes",
                    "initial": "J.G.",
                    "last": "Dias"
                },
                {
                    "first": "Miriam",
                    "initial": "M.",
                    "last": "Ramliden"
                },
                {
                    "first": "Csaba",
                    "initial": "C.",
                    "last": "K\u00f6dm\u00f6n"
                },
                {
                    "first": "Assimoula",
                    "initial": "A.",
                    "last": "Economopoulou"
                },
                {
                    "first": "Netta",
                    "initial": "N.",
                    "last": "Beer"
                },
                {
                    "first": "Lucia",
                    "initial": "L.",
                    "last": "Pastore Celentano"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2017.03.007",
            "firstpage": "2034",
            "issn": "0264410X",
            "lastpage": "2041",
            "pmid": "28314560",
            "pub_year": 2017,
            "title": "The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004\u20132014",
            "volume": "35"
        },
        "b0025": null,
        "b0030": {
            "authors": [
                {
                    "first": "Idris",
                    "initial": "I.",
                    "last": "Mohammed"
                },
                {
                    "first": "Garba",
                    "initial": "G.",
                    "last": "Iliyasu"
                },
                {
                    "first": "Abdulrazaq Garba",
                    "initial": "A.G.",
                    "last": "Habib"
                }
            ],
            "doi": "10.1080/20477724.2016.1274068",
            "firstpage": "1",
            "issn": "20477724",
            "lastpage": "6",
            "pmid": "28081671",
            "pub_year": 2017,
            "title": "Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa",
            "volume": "111"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Ouli",
                    "initial": "O.",
                    "last": "Xie"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                },
                {
                    "first": "Judith E.",
                    "initial": "J.E.",
                    "last": "Mueller"
                },
                {
                    "first": "Gunnstein",
                    "initial": "G.",
                    "last": "Norheim"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.04.036",
            "firstpage": "2852",
            "issn": "0264410X",
            "lastpage": "2861",
            "pmid": "23623866",
            "pub_year": 2013,
            "title": "Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine",
            "volume": "31"
        },
        "b0040": {
            "authors": [
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Gabutti"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Stefanati"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Kuhdari"
                }
            ],
            "firstpage": "E116",
            "issn": "11212233",
            "lastpage": "E120",
            "pub_year": 2015,
            "title": "Epidemiology of Neisseria meningitidis infections: Case distribution by age and relevance of carriage",
            "volume": "56"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Michael J.",
                    "initial": "M.J.",
                    "last": "Smith"
                }
            ],
            "doi": "10.1517/14712590802538455",
            "firstpage": "1941",
            "issn": "14712598",
            "lastpage": "1946",
            "pmid": "18990080",
            "pub_year": 2008,
            "title": "Meningococcal tetravalent conjugate vaccine",
            "volume": "8"
        },
        "b0050": {
            "authors": [
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "van de Beek"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Cabellos"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Dzupova"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Klein"
                },
                {
                    "first": "A. T.",
                    "initial": "A.T.",
                    "last": "Kloek"
                },
                {
                    "first": "S. L.",
                    "initial": "S.L.",
                    "last": "Leib"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Mourvillier"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Ostergaard"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Pagliano"
                },
                {
                    "first": "H. W.",
                    "initial": "H.W.",
                    "last": "Pfister"
                },
                {
                    "first": "R. C.",
                    "initial": "R.C.",
                    "last": "Read"
                },
                {
                    "first": "O. Resat",
                    "initial": "O.R.",
                    "last": "Sipahi"
                },
                {
                    "first": "M. C.",
                    "initial": "M.C.",
                    "last": "Brouwer"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.cmi.2016.01.007",
            "firstpage": "S37",
            "issn": "1198743X",
            "lastpage": "S62",
            "pmid": "27062097",
            "pub_year": 2016,
            "title": "ESCMID guideline: Diagnosis and treatment of acute bacterial meningitis",
            "volume": "22"
        },
        "b0055": null,
        "b0060": {
            "authors": [
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Crum-Cianflone"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Sullivan"
                }
            ],
            "doi": "10.1007/s40121-016-0107-0",
            "firstpage": "89",
            "issn": "21938229",
            "lastpage": "112",
            "pub_year": 2016,
            "title": "Meningococcal Vaccinations",
            "volume": "5"
        },
        "b0065": null,
        "b0070": {
            "authors": [
                {
                    "first": "Aia",
                    "initial": "A.",
                    "last": "Assaf-Casals"
                },
                {
                    "first": "Ghassan",
                    "initial": "G.",
                    "last": "Dbaibo"
                }
            ],
            "doi": "10.1080/21645515.2016.1143157",
            "firstpage": "1825",
            "issn": "21645515",
            "lastpage": "1837",
            "pmid": "26900984",
            "pub_year": 2016,
            "title": "Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix\u2122): A review of its immunogenicity, safety, co-administration, and antibody persistence",
            "volume": "12"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Jamie D.",
                    "initial": "J.D.",
                    "last": "Croxtall"
                },
                {
                    "first": "Sohita",
                    "initial": "S.",
                    "last": "Dhillon"
                }
            ],
            "doi": "10.2165/11209580-000000000-00000",
            "firstpage": "2407",
            "issn": "00126667",
            "lastpage": "2430",
            "pmid": "23231026",
            "pub_year": 2012,
            "title": "Meningococcal quadrivalent (Serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix\u2122)",
            "volume": "72"
        },
        "b0080": null,
        "b0085": {
            "authors": [
                {
                    "first": "Jose Manuel",
                    "initial": "J.M.",
                    "last": "Merino Arribas"
                },
                {
                    "first": "Alfonso",
                    "initial": "A.",
                    "last": "Carmona Mart\u00ednez"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Horn"
                },
                {
                    "first": "Xavier Maria",
                    "initial": "X.M.",
                    "last": "Perez Porcuna"
                },
                {
                    "first": "Maria Del Carmen",
                    "initial": "M.D.C.",
                    "last": "Otero Reigada"
                },
                {
                    "first": "Josep",
                    "initial": "J.",
                    "last": "Mar\u00e8s Berm\u00fadez"
                },
                {
                    "first": "Fernando",
                    "initial": "F.",
                    "last": "Centeno Malfaz"
                },
                {
                    "first": "Mariano",
                    "initial": "M.",
                    "last": "Miranda"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Mendez"
                },
                {
                    "first": "Miguel Angel",
                    "initial": "M.A.",
                    "last": "Garcia Cabezas"
                },
                {
                    "first": "Christoph",
                    "initial": "C.",
                    "last": "Wittermann"
                },
                {
                    "first": "Gerhard",
                    "initial": "G.",
                    "last": "Bleckmann"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Fischbach"
                },
                {
                    "first": "Devayani",
                    "initial": "D.",
                    "last": "Kolhe"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                }
            ],
            "doi": "10.1097/INF.0000000000001484",
            "firstpage": "e98",
            "issn": "08913668",
            "lastpage": "e107",
            "pmid": "28002359",
            "pub_year": 2017,
            "title": "Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial",
            "volume": "36"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1128/CDLI.10.5.780-786.2003",
            "firstpage": "780",
            "issn": "1071412X",
            "lastpage": "786",
            "pmid": "12965904",
            "pub_year": 2003,
            "title": "Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England",
            "volume": "10"
        },
        "b0095": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Goldschneider"
                },
                {
                    "first": "E. C.",
                    "initial": "E.C.",
                    "last": "Gotschlich"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Artenstein"
                }
            ],
            "doi": "10.1084/jem.129.6.1307",
            "firstpage": "1307",
            "issn": "00221007",
            "lastpage": "1326",
            "pmid": "4977280",
            "pub_year": 1969,
            "title": "Human immunity to the meningococcus. I. The role of humoral antibodies.",
            "volume": "129"
        },
        "b0100": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Goldschneider"
                },
                {
                    "first": "E. C.",
                    "initial": "E.C.",
                    "last": "Gotschlich"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Artenstein"
                }
            ],
            "doi": "10.1084/jem.129.6.1327",
            "firstpage": "1327",
            "issn": "00221007",
            "lastpage": "1348",
            "pmid": "4977281",
            "pub_year": 1969,
            "title": "Human immunity to the meningococcus. II. Development of natural immunity.",
            "volume": "129"
        },
        "b0105": {
            "authors": [
                {
                    "first": "E. D.G.",
                    "initial": "E.D.G.",
                    "last": "McIntosh"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Br\u00f6ker"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Wassil"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Welsch"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.07.019",
            "firstpage": "4414",
            "issn": "0264410X",
            "lastpage": "4421",
            "pmid": "26187262",
            "pub_year": 2015,
            "title": "Serum bactericidal antibody assays - The role of complement in infection and immunity",
            "volume": "33"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Pantazi-Chatzikonstantinou"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Pfletschinger"
                },
                {
                    "first": "Irmingard",
                    "initial": "I.",
                    "last": "Tichmann-Schumann"
                },
                {
                    "first": "Hartwig",
                    "initial": "H.",
                    "last": "Maurer"
                },
                {
                    "first": "Lothar",
                    "initial": "L.",
                    "last": "Maurer"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Fischbach"
                },
                {
                    "first": "Henrike",
                    "initial": "H.",
                    "last": "Zinke"
                },
                {
                    "first": "Heidemarie",
                    "initial": "H.",
                    "last": "Pankow-Culot"
                },
                {
                    "first": "Vassiliki",
                    "initial": "V.",
                    "last": "Papaevangelou"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van der Wielen"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.03.009",
            "firstpage": "4264",
            "issn": "0264410X",
            "lastpage": "4273",
            "pmid": "21420417",
            "pub_year": 2011,
            "title": "An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix\u2122 hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children",
            "volume": "29"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Guillermo M.",
                    "initial": "G.M.",
                    "last": "Ruiz-Palacios"
                },
                {
                    "first": "Li Min",
                    "initial": "L.M.",
                    "last": "Huang"
                },
                {
                    "first": "Tzou Yien",
                    "initial": "T.Y.",
                    "last": "Lin"
                },
                {
                    "first": "Lorena",
                    "initial": "L.",
                    "last": "Hernandez"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Lourdes Guerrero"
                },
                {
                    "first": "Antonio Lavalle",
                    "initial": "A.L.",
                    "last": "Villalobos"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Moreira"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Fissette"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1097/INF.0b013e3182784143",
            "firstpage": "62",
            "issn": "08913668",
            "lastpage": "71",
            "pmid": "23076383",
            "pub_year": 2013,
            "title": "Immunogenicity and safety of a booster dose of the 10-valent pneumococcal haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and y tetanus toxoid conjugate vaccine in toddlers: A randomized trial",
            "volume": "32"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Karvonen"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van der Wielen"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.03.043",
            "firstpage": "4274",
            "issn": "0264410X",
            "lastpage": "4284",
            "pmid": "21443965",
            "pub_year": 2011,
            "title": "Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial",
            "volume": "29"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Gianni",
                    "initial": "G.",
                    "last": "Bona"
                },
                {
                    "first": "Paolo",
                    "initial": "P.",
                    "last": "Castiglia"
                },
                {
                    "first": "Giorgio",
                    "initial": "G.",
                    "last": "Zoppi"
                },
                {
                    "first": "Maurizio",
                    "initial": "M.",
                    "last": "de Martino"
                },
                {
                    "first": "Annaelisa",
                    "initial": "A.",
                    "last": "Tasciotti"
                },
                {
                    "first": "Diego",
                    "initial": "D.",
                    "last": "D'Agostino"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Han"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.05.009",
            "firstpage": "3363",
            "issn": "0264410X",
            "lastpage": "3370",
            "pmid": "27181507",
            "pub_year": 2016,
            "title": "Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers",
            "volume": "34"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Forst\u00e9n"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Boutriau"
                },
                {
                    "first": "V\u00e9ronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Miller"
                }
            ],
            "doi": "10.4161/hv.22166",
            "firstpage": "1892",
            "issn": "21645515",
            "lastpage": "1903",
            "pmid": "23032159",
            "pub_year": 2012,
            "title": "Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers",
            "volume": "8"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Keith S.",
                    "initial": "K.S.",
                    "last": "Reisinger"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Johnston"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrljin"
                },
                {
                    "first": "Christopher J.",
                    "initial": "C.J.",
                    "last": "Gill"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Bedell"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1097/INF.0b013e31823dce5c",
            "firstpage": "64",
            "issn": "08913668",
            "lastpage": "74",
            "pmid": "22094635",
            "pub_year": 2012,
            "title": "Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants",
            "volume": "31"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Susanne P.",
                    "initial": "S.P.",
                    "last": "Stoof"
                },
                {
                    "first": "Fiona R.M.",
                    "initial": "F.R.M.",
                    "last": "Van Der Klis"
                },
                {
                    "first": "Debbie M.",
                    "initial": "D.M.",
                    "last": "Van Rooijen"
                },
                {
                    "first": "Mirjam J.",
                    "initial": "M.J.",
                    "last": "Knol"
                },
                {
                    "first": "Elisabeth A.M.",
                    "initial": "E.A.M.",
                    "last": "Sanders"
                },
                {
                    "first": "Guy A.M.",
                    "initial": "G.A.M.",
                    "last": "Berbers"
                }
            ],
            "doi": "10.1371/journal.pone.0100651",
            "issn": "19326203",
            "pmid": "24963638",
            "pub_year": 2014,
            "title": "Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers",
            "volume": "9"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Bertrand",
                    "initial": "B.",
                    "last": "Chevallier"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Jerzy",
                    "initial": "J.",
                    "last": "Brzostek"
                },
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Bermal"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Aristegui"
                },
                {
                    "first": "Dorota",
                    "initial": "D.",
                    "last": "Borys"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Cleerbout"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1097/INF.0b013e318199f62d",
            "firstpage": "S109",
            "issn": "08913668",
            "lastpage": "S118",
            "pmid": "19325447",
            "pub_year": 2009,
            "title": "Safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines",
            "volume": "28"
        },
        "b0150": {
            "authors": [
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Saenger"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Maechler"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Potreck"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Zepp"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Habermehl"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1016/j.vaccine.2004.08.030",
            "firstpage": "1135",
            "issn": "0264410X",
            "lastpage": "1143",
            "pmid": "15629356",
            "pub_year": 2005,
            "title": "Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately",
            "volume": "23"
        },
        "b0155": {
            "authors": [
                {
                    "first": "David S.",
                    "initial": "D.S.",
                    "last": "Stephens"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "Petter",
                    "initial": "P.",
                    "last": "Brandtzaeg"
                }
            ],
            "doi": "10.1016/S0140-6736(07)61016-2",
            "firstpage": "2196",
            "issn": "01406736",
            "lastpage": "2210",
            "pmid": "17604802",
            "pub_year": 2007,
            "title": "Epidemic meningitis, meningococcaemia, and Neisseria meningitidis",
            "volume": "369"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Mehmet",
                    "initial": "M.",
                    "last": "Ceyhan"
                },
                {
                    "first": "Sameh",
                    "initial": "S.",
                    "last": "Anis"
                },
                {
                    "first": "Latt",
                    "initial": "L.",
                    "last": "Htun-Myint"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Pawinski"
                },
                {
                    "first": "Montse",
                    "initial": "M.",
                    "last": "Soriano-Gabarr\u00f3"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Vyse"
                }
            ],
            "doi": "10.1016/j.ijid.2012.03.011",
            "firstpage": "e574",
            "issn": "12019712",
            "lastpage": "e582",
            "pmid": "22647750",
            "pub_year": 2012,
            "title": "Meningococcal disease in the Middle East and North Africa: An important public health consideration that requires further attention",
            "volume": "16"
        },
        "b0165": {
            "authors": [
                {
                    "first": "William P.",
                    "initial": "W.P.",
                    "last": "Hausdorff"
                },
                {
                    "first": "Rana",
                    "initial": "R.",
                    "last": "Hajjeh"
                },
                {
                    "first": "Abdulrahman",
                    "initial": "A.",
                    "last": "Al-Mazrou"
                },
                {
                    "first": "Atef",
                    "initial": "A.",
                    "last": "Shibl"
                },
                {
                    "first": "Montse",
                    "initial": "M.",
                    "last": "Soriano-Gabarro"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.11.018",
            "firstpage": "1935",
            "issn": "0264410X",
            "lastpage": "1944",
            "pmid": "17241707",
            "pub_year": 2007,
            "title": "The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) Region-Current status and needs",
            "volume": "25"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Ricardo Walter",
                    "initial": "R.W.",
                    "last": "Ruttimann"
                },
                {
                    "first": "Angela",
                    "initial": "A.",
                    "last": "Gentile"
                },
                {
                    "first": "Mercedes Macias",
                    "initial": "M.M.",
                    "last": "Parra"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Saez-Llorens"
                },
                {
                    "first": "Marco Aurelio Palazzi",
                    "initial": "M.A.P.",
                    "last": "Safadi"
                },
                {
                    "first": "Maria Elena",
                    "initial": "M.E.",
                    "last": "Santolaya"
                }
            ],
            "doi": "10.1097/INF.0000000000000228",
            "firstpage": "284",
            "issn": "08913668",
            "lastpage": "290",
            "pmid": "24463807",
            "pub_year": 2014,
            "title": "A consensus statement: Meningococcal disease among infants, children and adolescents in Latin America",
            "volume": "33"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Marco Aur\u00e9lio P.",
                    "initial": "M.A.P.",
                    "last": "S\u00e1fadi"
                },
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "O'Ryan"
                },
                {
                    "first": "Maria Teresa",
                    "initial": "M.T.",
                    "last": "Valenzuela Bravo"
                },
                {
                    "first": "Maria Cristina C.",
                    "initial": "M.C.C.",
                    "last": "Brandileone"
                },
                {
                    "first": "Maria Cec\u00edlia O.",
                    "initial": "M.C.O.",
                    "last": "Gorla"
                },
                {
                    "first": "Ana Paula S.",
                    "initial": "A.P.S.",
                    "last": "de Lemos"
                },
                {
                    "first": "Gabriela",
                    "initial": "G.",
                    "last": "Moreno"
                },
                {
                    "first": "Julio A.",
                    "initial": "J.A.",
                    "last": "Vazquez"
                },
                {
                    "first": "Eduardo L.",
                    "initial": "E.L.",
                    "last": "L\u00f3pez"
                },
                {
                    "first": "Muhamed Kheir",
                    "initial": "M.K.",
                    "last": "Taha"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2015.10.055",
            "firstpage": "6529",
            "issn": "0264410X",
            "lastpage": "6536",
            "pmid": "26597036",
            "pub_year": 2015,
            "title": "The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations",
            "volume": "33"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Marco Aur\u00e9lio P.",
                    "initial": "M.A.P.",
                    "last": "S\u00e1fadi"
                },
                {
                    "first": "Luz Elena Espinosa",
                    "initial": "L.E.E.",
                    "last": "De Los Monteros"
                },
                {
                    "first": "Eduardo Luis",
                    "initial": "E.L.",
                    "last": "L\u00f3pez"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "S\u00e0ez-Llorens"
                },
                {
                    "first": "Ana Paula",
                    "initial": "A.P.",
                    "last": "Lemos"
                },
                {
                    "first": "Sarbelio",
                    "initial": "S.",
                    "last": "Moreno-Espinosa"
                },
                {
                    "first": "Silvia Gonz\u00e1lez",
                    "initial": "S.G.",
                    "last": "Ayala"
                },
                {
                    "first": "Juan Pablo",
                    "initial": "J.P.",
                    "last": "Torres"
                },
                {
                    "first": "Jos\u00e9 Cassio",
                    "initial": "J.C.",
                    "last": "De Moraes"
                },
                {
                    "first": "Julio Alberto",
                    "initial": "J.A.",
                    "last": "V\u00e1zquez"
                }
            ],
            "doi": "10.1586/14760584.2013.814879",
            "firstpage": "903",
            "issn": "14760584",
            "lastpage": "915",
            "pmid": "23909747",
            "pub_year": 2013,
            "title": "The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative",
            "volume": "12"
        },
        "b0185": null,
        "b0190": {
            "authors": [
                {
                    "first": "Andromachi",
                    "initial": "A.",
                    "last": "Karachaliou"
                },
                {
                    "first": "Andrew J.K.",
                    "initial": "A.J.K.",
                    "last": "Conlan"
                },
                {
                    "first": "Marie Pierre",
                    "initial": "M.P.",
                    "last": "Preziosi"
                },
                {
                    "first": "Caroline L.",
                    "initial": "C.L.",
                    "last": "Trotter"
                }
            ],
            "doi": "10.1093/cid/civ508",
            "firstpage": "S594",
            "issn": "10584838",
            "lastpage": "S600",
            "pmid": "26553693",
            "pub_year": 2015,
            "title": "Modeling long-term vaccination strategies with MenAfriVac in the African Meningitis Belt",
            "volume": "61"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Pascal R.",
                    "initial": "P.R.",
                    "last": "Lestrate"
                },
                {
                    "first": "Aftab",
                    "initial": "A.",
                    "last": "Naz"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Blatter"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1097/INF.0b013e31828693c5",
            "firstpage": "760",
            "issn": "08913668",
            "lastpage": "767",
            "pmid": "23348814",
            "pub_year": 2013,
            "title": "One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and y tetanus toxoid conjugate vaccine is immunogenic in 9-to 12-month-old children",
            "volume": "32"
        }
    },
    "body_text": [
        {
            "endOffset": 26386,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 26385,
                    "startOffset": 26381
                }
            },
            "secId": "s0005",
            "sentence": "Three quadrivalent meningococcal conjugate vaccines using diphtheria toxoid (MenACWY-DT; Menactra, Sanofi Pasteur), non-toxic diphtheria cross-reacting mutant CRM197 (MenACWY-CRM; Menveo, GSK), or tetanus toxoid (MenACWY-TT; Nimenrix, Pfizer) as carrier proteins are approved for use in different age groups, including infants [12].",
            "startOffset": 26054,
            "title": "Introduction"
        },
        {
            "endOffset": 35436,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "One month post-vaccination, \u226589.7% of the ACWY1 ATP subset for hSBA had hSBA titers \u2265 4 for each meningococcal serogroup (Table 2).",
            "startOffset": 35305,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 41400,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 41399,
                    "startOffset": 41395
                },
                "b0135": {
                    "endOffset": 41238,
                    "startOffset": 41234
                }
            },
            "secId": "s0070",
            "sentence": "Our results also compare well with those observed for co-administration of MenACWY-CRM197 with routine pediatric vaccines according to the same 3+1 schedule [27] and confirm that co-administration of MenACWY-TT with PHiD-CV during the first years of life does not affect the immunogenicity of the pneumococcal vaccine [17].",
            "startOffset": 41077,
            "title": "Discussion"
        },
        {
            "endOffset": 31902,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The target sample size for the evaluation of the primary objective was 300 infants in group ACWY3+1.",
            "startOffset": 31802,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 43913,
            "parents": [],
            "secId": "s0070",
            "sentence": "Our results support expanding the use of MenACWY-TT to predominantly non-European populations, and as part of NIPs worldwide.",
            "startOffset": 43788,
            "title": "Discussion"
        },
        {
            "endOffset": 36240,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Immune responses to MenACWY-TT by country are presented in Text S3.",
            "startOffset": 36173,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 32484,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Safety was assessed in the primary and booster total vaccinated cohorts, which included all participants with \u22651 primary and booster dose(s) with any of the study vaccines, respectively.",
            "startOffset": 32298,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 42361,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 42360,
                    "startOffset": 42353
                },
                "b0150": {
                    "endOffset": 42360,
                    "startOffset": 42353
                }
            },
            "secId": "s0070",
            "sentence": "For both PHiD-CV and DTPa-IPV/Hib, the most frequently reported solicited symptom was pain, in contrast with other studies where redness was more frequent [29,30].",
            "startOffset": 42198,
            "title": "Discussion"
        },
        {
            "endOffset": 25684,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 25683,
                    "startOffset": 25680
                }
            },
            "secId": "s0005",
            "sentence": "The incidence of IMD remains high, with more than 1.2 million cases per year reported worldwide [2].",
            "startOffset": 25584,
            "title": "Introduction"
        },
        {
            "endOffset": 31468,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Immune responses to co-administered vaccines was assessed in randomized exclusive subsets of 25% of participants by neutralization (for polio) or enzyme-linked immunosorbent assay (all other antigens), using the thresholds presented in Table S1.",
            "startOffset": 31223,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 43453,
            "parents": [],
            "refoffsets": {
                "b0185": {
                    "endOffset": 43452,
                    "startOffset": 43448
                }
            },
            "secId": "s0070",
            "sentence": "Despite the risk of IMD, meningococcal vaccination with quadrivalent vaccines is currently included in the NIPs of very few countries in these regions [37].",
            "startOffset": 43297,
            "title": "Discussion"
        },
        {
            "endOffset": 30575,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The post-primary immunogenicity of co-administered vaccines and post-booster anti-tetanus immune response and immunogenicity of PHiD-CV in subsets of participants, safety and reactogenicity were also assessed.",
            "startOffset": 30366,
            "title": "Study objectives"
        },
        {
            "endOffset": 32047,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Assuming a drop-out/non-evaluable rate of 20% post-primary vaccination, a total target sample size of 750 infants was calculated for enrollment.",
            "startOffset": 31903,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 28132,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Group ACWY1 received a single dose at 15\u201318 months of age and served as control.",
            "startOffset": 28052,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29151,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.",
            "startOffset": 29042,
            "title": "Study design and participants"
        },
        {
            "endOffset": 38900,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "One fatal SAE (sudden infant death syndrome, not-related to vaccination) was reported in group ACWY1, 39 days after the second dose of PHiD-CV and DTPa-IPV/Hib.",
            "startOffset": 38740,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 26972,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 26971,
                    "startOffset": 26967
                }
            },
            "secId": "s0005",
            "sentence": "Co-administration of MenACWY-TT with routine pediatric vaccines at 2, 3, 4 and 12 months of age or 2, 4 and 12 months of age was shown to induce adequate immune responses, as measured by serum bactericidal antibody assays with human (hSBA) and rabbit (rSBA) complement, with an acceptable safety profile in a European population [17].",
            "startOffset": 26638,
            "title": "Introduction"
        },
        {
            "endOffset": 29974,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The following statistical criterion, which was considered clinically relevant, was used: the lower limit (LL) of the 2-sided 95% confidence interval (CI) for the percentage of infants with rSBA titers \u22658 for each serogroup should be \u226580%.",
            "startOffset": 29736,
            "title": "Study objectives"
        },
        {
            "endOffset": 46826,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Conclusions"
                }
            ],
            "secId": "s0085",
            "sentence": "All authors had full access to the data and corresponding author had final responsibility to submit for publication.",
            "startOffset": 46710,
            "title": "Authors\u2019 contribution"
        },
        {
            "endOffset": 42934,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 42863,
                    "startOffset": 42854
                },
                "b0160": {
                    "endOffset": 42863,
                    "startOffset": 42854
                },
                "b0165": {
                    "endOffset": 42863,
                    "startOffset": 42854
                },
                "b0170": {
                    "endOffset": 42933,
                    "startOffset": 42929
                }
            },
            "secId": "s0070",
            "sentence": "Although data regarding the burden of IMD in Lebanon is scarce [2,32,33], the reported incidence was 0.14 per 100,000 inhabitants in 2013 [34].",
            "startOffset": 42791,
            "title": "Discussion"
        },
        {
            "endOffset": 38356,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "At least one new onset of chronic illnesses was reported for 4.3% of participants in each of the ACWY3+1 and ACWY1+1 groups and 2.1% of participants in group ACWY1 (Table S4).",
            "startOffset": 38181,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 45423,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 45422,
                    "startOffset": 45415
                },
                "b0195": {
                    "endOffset": 45422,
                    "startOffset": 45415
                }
            },
            "secId": "s0070",
            "sentence": "Previous reports showed that rSBA titers \u22658 were maintained up to 3 years post-vaccination in 90.8% of toddlers who had received MenACWY-TT at 12\u201323 months of age [26], although hSBA antibody levels are known to decline more rapidly following vaccination during the first 2 years of life, especially for MenA [26,39].",
            "startOffset": 45106,
            "title": "Discussion"
        },
        {
            "endOffset": 44840,
            "parents": [],
            "secId": "s0070",
            "sentence": "A quadrivalent control group could not be used, as no quadrivalent vaccines were licensed in the participating countries.",
            "startOffset": 44719,
            "title": "Discussion"
        },
        {
            "endOffset": 47550,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Conclusions"
                }
            ],
            "secId": "s0085",
            "sentence": "All authors participated in the drafting and approval of the manuscript.",
            "startOffset": 47478,
            "title": "Authors\u2019 contribution"
        },
        {
            "endOffset": 35824,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "For each serogroup, hSBA booster responses rates were \u226594.3% and \u226591.8% in groups ACWY3+1 and ACWY1+1, respectively, and vaccine response rates of \u226587.9% were observed in group ACWY1 (Fig. 2B).",
            "startOffset": 35631,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 35021,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Vaccine response rates in group ACWY1 were \u226594.7% for all serogroups (Fig. 2B).",
            "startOffset": 34942,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 45524,
            "parents": [],
            "secId": "s0070",
            "sentence": "Also, the sample size for immunogenicity assessments of co-administered vaccines was relatively low.",
            "startOffset": 45424,
            "title": "Discussion"
        },
        {
            "endOffset": 46614,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Conclusions"
                }
            ],
            "secId": "s0080",
            "sentence": "Menactra is a trademark of Sanofi Pasteur.",
            "startOffset": 46572,
            "title": "Trademark statement"
        },
        {
            "endOffset": 33427,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "However, the results of these analyses should be interpreted with caution, as no adjustment for multiplicity was performed.",
            "startOffset": 33304,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 25396,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 25395,
                    "startOffset": 25390
                },
                "b0015": {
                    "endOffset": 25395,
                    "startOffset": 25390
                },
                "b0020": {
                    "endOffset": 25395,
                    "startOffset": 25390
                }
            },
            "secId": "s0005",
            "sentence": "MenA and MenC are more prominent in Asia, MenB and MenC in Europe, Australia and South America, while in North America, MenB, MenC and MenY prevalence is higher [2\u20134].",
            "startOffset": 25229,
            "title": "Introduction"
        },
        {
            "endOffset": 27867,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Infants were randomized (2:1:1) into 3 groups to receive MenACWY-TT according to different schedules.",
            "startOffset": 27766,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37333,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "In the ACWY1 group, pain was reported by 53.0% (DTPa-IPV/Hib) and 52.1% (PHiD-CV) of participants.",
            "startOffset": 37235,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 31223,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "rSBA/hSBA booster and vaccine response to MenACWY-TT in previously-primed groups and group ACWY1, respectively, was defined as a post-vaccination titer of \u226532 (rSBA)/\u22658 (hSBA) for initially seronegative participants or as a \u22654-fold increase for initially seropositive participants.",
            "startOffset": 30942,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 39073,
            "parents": [],
            "secId": "s0070",
            "sentence": "This study demonstrated that primary vaccination with 3 doses of MenACWY-TT was immunogenic when co-administered with PHiD-CV and DTPa-IPV/Hib in healthy infants.",
            "startOffset": 38911,
            "title": "Discussion"
        },
        {
            "endOffset": 45938,
            "parents": [],
            "secId": "s0075",
            "sentence": "Regardless of the primary vaccination schedule received, \u226596.3% of children had rSBA titers \u2265 8 after 1 dose of MenACWY-TT at 15\u201318 months of age, showing that immune response to MenACWY-TT vaccination in toddlers is not affected by the number of previously-administered doses.",
            "startOffset": 45661,
            "title": "Conclusions"
        },
        {
            "endOffset": 28769,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Treatment allocation was performed at the investigators\u2019 site using an internet-based system, using a minimization algorithm accounting for center.",
            "startOffset": 28622,
            "title": "Study design and participants"
        },
        {
            "endOffset": 45660,
            "parents": [],
            "secId": "s0075",
            "sentence": "MenACWY-TT was immunogenic in healthy infants after 3 primary doses at 2, 4 and 6 months or after 1 dose at 6 months of age.",
            "startOffset": 45536,
            "title": "Conclusions"
        },
        {
            "endOffset": 32613,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Immunogenicity was evaluated in all children or different subsets of the according-to-protocol (ATP) cohorts (Table S1; Fig. 1).",
            "startOffset": 32485,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33627,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "From the 753 enrolled infants, 750 and 678 were vaccinated in the primary and booster phase, respectively and 659 completed the study (Fig. 1).",
            "startOffset": 33484,
            "title": "Demographics"
        },
        {
            "endOffset": 34802,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "After the MenACWY-TT dose, rSBA GMTs ranged between 768.1 (MenC) and 5240.7 (MenW) in group ACWY1 (Fig. 2A).",
            "startOffset": 34694,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 46975,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Conclusions"
                }
            ],
            "secId": "s0085",
            "sentence": "Drafts were developed by a professional publication writer according to the recommendations, documentation, and outline provided by the lead author.",
            "startOffset": 46827,
            "title": "Authors\u2019 contribution"
        },
        {
            "endOffset": 39816,
            "parents": [],
            "secId": "s0070",
            "sentence": "Following MenACWY-TT vaccination at this age, \u226596% of children had rSBA titers \u22658, regardless of primary vaccination.",
            "startOffset": 39699,
            "title": "Discussion"
        },
        {
            "endOffset": 34390,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Post-vaccination with MenACWY-TT, \u226596.3% of children in group ACWY1 had rSBA titers \u2265 8 (Table 1).",
            "startOffset": 34292,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 39585,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 39584,
                    "startOffset": 39580
                }
            },
            "secId": "s0070",
            "sentence": "These results further support previous findings in infants; either 3 or 2 primary doses of MenACWY-TT were immunogenic in healthy European infants, when co-administered with PHiD-CV and DTPa-HBV-IPV/Hib, with \u226593% of children achieving rSBA titers \u2265 8 for all serogroups, at 5 months of age [17].",
            "startOffset": 39289,
            "title": "Discussion"
        },
        {
            "endOffset": 35631,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "For all groups, hSBA GMTs increased compared with pre-booster/pre-vaccination values, with higher GMTs and respective fold increases observed in groups primed with MenACWY-TT (Table 2, Fig. 2A).",
            "startOffset": 35437,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 28051,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Two groups received a 3-dose (at 2, 4 and 6 months of age; group ACWY3+1) or a 1-dose (6 months of age; group ACWY1+1) primary schedule followed by a booster dose at age 15\u201318 months.",
            "startOffset": 27868,
            "title": "Study design and participants"
        },
        {
            "endOffset": 26637,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 26636,
                    "startOffset": 26632
                }
            },
            "secId": "s0005",
            "sentence": "Recently, the vaccine was prequalified by the World Health Organization [16].",
            "startOffset": 26560,
            "title": "Introduction"
        },
        {
            "endOffset": 39288,
            "parents": [],
            "secId": "s0070",
            "sentence": "Following 3 doses of MenACWY-TT at 2, 4 and 6 months or 1 dose at 6 months of age, \u226593% of infants achieved rSBA titers \u22658 for each meningococcal serogroup, which is an adequate basis to assume clinical protection.",
            "startOffset": 39074,
            "title": "Discussion"
        },
        {
            "endOffset": 28462,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The trial included a primary vaccination phase (up to 7 months of age), a booster phase (14\u201319 months of age) and a 6-month extended safety follow-up (Fig. 1).",
            "startOffset": 28303,
            "title": "Study design and participants"
        },
        {
            "endOffset": 25855,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 25854,
                    "startOffset": 25849
                },
                "b0045": {
                    "endOffset": 25854,
                    "startOffset": 25849
                }
            },
            "secId": "s0005",
            "sentence": "Children aged <5 years are at particular risk of IMD, and the highest rate of disease is recorded in infants, while a second, lower peak is observed in adolescents [8,9].",
            "startOffset": 25685,
            "title": "Introduction"
        },
        {
            "endOffset": 33461,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Analyses were performed using SAS.",
            "startOffset": 33427,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 42790,
            "parents": [],
            "secId": "s0070",
            "sentence": "Meningococcal vaccination is not currently included in the NIPs of either Lebanon or Mexico.",
            "startOffset": 42698,
            "title": "Discussion"
        },
        {
            "endOffset": 38031,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "At least one unsolicited AE was reported after \u226445.7% of primary doses, and in \u226455.4% of participants, post-booster vaccination, in the 3 groups.",
            "startOffset": 37886,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 39971,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 39970,
                    "startOffset": 39963
                },
                "b0115": {
                    "endOffset": 39970,
                    "startOffset": 39963
                },
                "b0120": {
                    "endOffset": 39970,
                    "startOffset": 39963
                }
            },
            "secId": "s0070",
            "sentence": "Moreover, immunogenicity of MenACWY-TT did not seem impacted by co-administration with other pediatric vaccines, as previously shown for toddlers [22\u201324].",
            "startOffset": 39817,
            "title": "Discussion"
        },
        {
            "endOffset": 27766,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This phase IIIb, open, controlled, randomized study was conducted between January 2012 and October 2015 in 2 centers in Lebanon and Mexico.",
            "startOffset": 27627,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35304,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "One month post-booster dose, these titers were observed for all evaluable participants in groups ACWY3+1 and ACWY1+1.",
            "startOffset": 35187,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 42562,
            "parents": [],
            "secId": "s0070",
            "sentence": "No SAEs were assessed as related to vaccination.",
            "startOffset": 42514,
            "title": "Discussion"
        },
        {
            "endOffset": 28846,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All personnel in charge of laboratory testing were blinded to the treatment.",
            "startOffset": 28770,
            "title": "Study design and participants"
        },
        {
            "endOffset": 40181,
            "parents": [],
            "secId": "s0070",
            "sentence": "Overall, the percentage of children with rSBA titers \u22658 at 7 or 15\u201318 months of age was not affected by the number of doses of MenACWY-TT, nor was there a significant difference in the booster/vaccine response.",
            "startOffset": 39971,
            "title": "Discussion"
        },
        {
            "endOffset": 43787,
            "parents": [],
            "refoffsets": {
                "b0185": {
                    "endOffset": 43639,
                    "startOffset": 43635
                },
                "b0190": {
                    "endOffset": 43541,
                    "startOffset": 43537
                }
            },
            "secId": "s0070",
            "sentence": "While MenA vaccination was successfully implemented in the African meningitis belt [38] and MenC/MenACWY vaccination is used as outbreak response in some countries in Latin America [37], there is an unmet need in adapting current meningococcal vaccination recommendations to serogroup prevalence specific to each geographic location.",
            "startOffset": 43454,
            "title": "Discussion"
        },
        {
            "endOffset": 25007,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 25006,
                    "startOffset": 25003
                }
            },
            "secId": "s0005",
            "sentence": "Invasive meningococcal disease (IMD) is a life-threatening condition which, if left untreated, can lead to a case fatality ratio of up to 50% [1].",
            "startOffset": 24861,
            "title": "Introduction"
        },
        {
            "endOffset": 35186,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "One month post-primary vaccination, in the ATP subsets for hSBA, 100% (ACWY3+1) and \u226587.2% (ACWY1+1) of children had hSBA titers \u22654 for each meningococcal serogroup.",
            "startOffset": 35021,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 36173,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "For each serogroup, hSBA GMTs were higher with increasing number of MenACWY-TT doses received.",
            "startOffset": 36079,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 36822,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Post-primary GMCs did not differ between the ACWY3+1 and ACWY1 groups (Table 3).",
            "startOffset": 36742,
            "title": "Immune responses to co-administered vaccines"
        },
        {
            "endOffset": 27314,
            "parents": [],
            "secId": "s0005",
            "sentence": "We studied co-administration of MenACWY-TT with a pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV; Synflorix, GSK) and a combined diphtheria, tetanus, acellular pertussis, inactivated polio and H. influenzae type b vaccine (DTPa-IPV/Hib; Infanrix-IPV/Hib, GSK) in healthy infants from Lebanon and Mexico.",
            "startOffset": 26972,
            "title": "Introduction"
        },
        {
            "endOffset": 36078,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Also, GMTs for MenC were higher in the previously-primed groups, post-booster dose compared to group ACWY1, post-vaccination.",
            "startOffset": 35953,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 40365,
            "parents": [],
            "secId": "s0070",
            "sentence": "However, post-primary rSBA GMTs for MenC appeared to increase with the number of primary doses and post-booster MenC GMTs were higher in the primed groups compared to the na\u00efve group.",
            "startOffset": 40182,
            "title": "Discussion"
        },
        {
            "endOffset": 29042,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Vaccines were administered intramuscularly, into the upper-left (MenACWY-TT), upper-right (PHiD-CV) or lower-right (DTPa-IPV/Hib) anterolateral thigh; vaccine compositions are detailed in Text S2.",
            "startOffset": 28846,
            "title": "Study design and participants"
        },
        {
            "endOffset": 46571,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Conclusions"
                }
            ],
            "secId": "s0080",
            "sentence": "Menveo, Synflorix and Infanrix-IPV/Hib are trademarks owned by the GSK group of companies.",
            "startOffset": 46481,
            "title": "Trademark statement"
        },
        {
            "endOffset": 39698,
            "parents": [],
            "secId": "s0070",
            "sentence": "At 15\u201318 months of age, rSBA titers \u22658 were maintained in \u226565% of participants previously primed with MenACWY-TT.",
            "startOffset": 39585,
            "title": "Discussion"
        },
        {
            "endOffset": 28570,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Participants were healthy infants aged 6\u201312 weeks at enrollment, born after a gestation period of \u226536 weeks.",
            "startOffset": 28462,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37234,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "Post-primary vaccination, the most frequently reported solicited local symptom was pain, after 41.4% and 33.0% of MenACWY-TT doses, 46.0% and 48.0% of PHiD-CV doses, and 45.7% and 48.1% of DTPa-IPV/Hib doses, in groups ACWY3+1 and ACWY1+1, respectively.",
            "startOffset": 36981,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 33303,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Potential group differences were indicated by the exclusion of 1 from the 95% CI on the GMT/GMC ratios (computed using an analysis of variance model on the log10 titers/concentrations transformation) and the exclusion of 0 from the 95% CI on the differences in vaccine response rates/percentage of children with titers/concentrations above pre-established thresholds.",
            "startOffset": 32936,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 29398,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The protocol and informed consent forms were reviewed and approved by an Independent Ethics Committee or Institutional Review Board at each center.",
            "startOffset": 29251,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37886,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "The most frequently reported solicited general symptom was irritability/fussiness, after 46.1%, 48.5% and 48.1% of doses post-primary vaccination and 33.1%, 32.7% and 36.5% of participants post-booster vaccination, in groups ACWY3+1, ACWY1+1 and ACWY1, respectively (Fig. 3).",
            "startOffset": 37611,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 38621,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "None of the events were considered vaccination-related by the investigator and all recovered/resolved by study end (Table S4).",
            "startOffset": 38495,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 47477,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Conclusions"
                }
            ],
            "secId": "s0085",
            "sentence": "MT and AJ participated in the analyses and interpretation of data, MW participated in the conception, design and planning of the study, supervised the analysis, participated in the interpretation of results.",
            "startOffset": 47270,
            "title": "Authors\u2019 contribution"
        },
        {
            "endOffset": 44429,
            "parents": [],
            "secId": "s0070",
            "sentence": "Moreover, the ACWY1 group was used as a control for the post-primary and pre-booster timepoints.",
            "startOffset": 44333,
            "title": "Discussion"
        },
        {
            "endOffset": 44553,
            "parents": [],
            "secId": "s0070",
            "sentence": "Immunogenicity endpoints were not assessed post-each dose in the ACWY3+1 group.",
            "startOffset": 44474,
            "title": "Discussion"
        },
        {
            "endOffset": 28302,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "As part of the study, all participants received DTPa-IPV/Hib and PHiD-CV at 2, 4, 6 and 15\u201318 months of age, according to national immunization programs (NIPs) (Fig. 1).",
            "startOffset": 28133,
            "title": "Study design and participants"
        },
        {
            "endOffset": 34291,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "One month after primary vaccination, for each meningococcal serogroup, \u226599.4% and \u226593.9% of participants had rSBA titers \u22658 in groups ACWY3+1 and ACWY1+1, respectively; at 15\u201318 months of age, these percentages were \u226568.8% and \u226565.6%, respectively, and at one month post-booster vaccination, \u226599.6% and \u226599.3%, respectively.",
            "startOffset": 33967,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 29250,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from each participant\u2019s parent/guardian prior to enrollment.",
            "startOffset": 29152,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32860,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Antibody concentrations/titers below the assay cut-off (Table S1) were given an arbitrary value of half the cut-off.",
            "startOffset": 32744,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 41569,
            "parents": [],
            "secId": "s0070",
            "sentence": "Although all children had protective anti-TT antibody concentrations after vaccination at age 15\u201318 months, antibody GMCs tended to be lower in MenACWY-TT-primed groups.",
            "startOffset": 41400,
            "title": "Discussion"
        },
        {
            "endOffset": 42129,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 42128,
                    "startOffset": 42124
                }
            },
            "secId": "s0070",
            "sentence": "A lower immune response to pneumococcal serotype 18C (conjugated to TT in PHiD-CV), although not evidenced in our study, was previously observed following co-administration of MenACWY-TT with PHiD-CV at 12\u201323 months of age and attributed to the effect of high TT dosage on the response to co-administrated TT-conjugated vaccines [23].",
            "startOffset": 41795,
            "title": "Discussion"
        },
        {
            "endOffset": 44718,
            "parents": [],
            "secId": "s0070",
            "sentence": "Therefore, only the cumulative effect of the 3 primary doses was demonstrated, and the immunogenicity of one or 2 MenACWY-TT doses in early infancy is not answered.",
            "startOffset": 44554,
            "title": "Discussion"
        },
        {
            "endOffset": 31690,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Solicited local and general symptoms (days 0\u20137) and unsolicited adverse events (AEs) (days 0\u201330) were recorded by parents on diary cards post-each vaccination and graded by intensity.",
            "startOffset": 31507,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 32743,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "GMTs/GM concentrations (GMCs) were calculated by taking the anti-log of the mean of the log10 titer/concentration transformations.",
            "startOffset": 32613,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 43296,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 43245,
                    "startOffset": 43238
                },
                "b0180": {
                    "endOffset": 43245,
                    "startOffset": 43238
                }
            },
            "secId": "s0070",
            "sentence": "In Mexico, IMD incidence is <0.1 cases per 100,000 inhabitants of all ages, but is likely to be underreported [35], with the most prominent serogroup being MenC, followed by MenW [35,36], similar to serogroup prevalence in Latin America.",
            "startOffset": 43059,
            "title": "Discussion"
        },
        {
            "endOffset": 30365,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Secondary objectives evaluated the immune responses to MenACWY-TT vaccination at 1 month post-primary vaccination (groups ACWY3+1 and ACWY1+1) and pre- and 1 month post-booster/single dose (all groups), in terms of percentage of children with titers above pre-specified thresholds, geometric mean titers (GMTs) and booster/vaccine response measured by rSBA and hSBA (subset of participants).",
            "startOffset": 29974,
            "title": "Study objectives"
        },
        {
            "endOffset": 29735,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The primary objective was to demonstrate that MenACWY-TT is immunogenic in infants after 3 primary doses, in terms of rSBA antibodies to each meningococcal serogroup.",
            "startOffset": 29569,
            "title": "Study objectives"
        },
        {
            "endOffset": 30741,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Approximately 5 mL of blood were collected from all participants, post-primary and pre- and post-booster/single dose vaccination (Fig. 1).",
            "startOffset": 30603,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 30942,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0090": {
                    "endOffset": 30930,
                    "startOffset": 30923
                },
                "b0095": {
                    "endOffset": 30930,
                    "startOffset": 30923
                },
                "b0100": {
                    "endOffset": 30930,
                    "startOffset": 30923
                },
                "b0105": {
                    "endOffset": 30930,
                    "startOffset": 30923
                }
            },
            "secId": "s0025",
            "sentence": "Antibody titers for each meningococcal serogroup were determined by rSBA and hSBA (in a randomized subset), with pre-specified thresholds for seropositivity of 8 and 4, respectively [18\u201321] (Table S1).",
            "startOffset": 30741,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 32935,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Between-group exploratory analyses compared immune responses to MenACWY-TT.",
            "startOffset": 32860,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 31779,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Serious AEs (SAEs) and new onset of chronic illnesses were recorded throughout the study.",
            "startOffset": 31690,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 27507,
            "parents": [],
            "secId": "s0005",
            "sentence": "The 3+1 primary-booster schedule at 2, 4, 6 and 15\u201318 months of age was designed to align with the priming schedule of other routine infant vaccines used in several countries across the world.",
            "startOffset": 27315,
            "title": "Introduction"
        },
        {
            "endOffset": 42513,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 42512,
                    "startOffset": 42508
                }
            },
            "secId": "s0070",
            "sentence": "Nevertheless, pain and redness were found to have similar incidence in a review on safety data of PHiD-CV co-administration with routine vaccines [31].",
            "startOffset": 42362,
            "title": "Discussion"
        },
        {
            "endOffset": 25584,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 25508,
                    "startOffset": 25503
                },
                "b0010": {
                    "endOffset": 25508,
                    "startOffset": 25503
                },
                "b0015": {
                    "endOffset": 25508,
                    "startOffset": 25503
                },
                "b0025": {
                    "endOffset": 25524,
                    "startOffset": 25519
                },
                "b0030": {
                    "endOffset": 25524,
                    "startOffset": 25519
                },
                "b0035": {
                    "endOffset": 25537,
                    "startOffset": 25534
                }
            },
            "secId": "s0005",
            "sentence": "In the African meningitis belt, MenW is the most common serogroup following a decrease in MenA prevalence [1\u20133], and MenC [5,6] and MenX [7] also emerging as serious causes of meningitis.",
            "startOffset": 25397,
            "title": "Introduction"
        },
        {
            "endOffset": 46462,
            "parents": [],
            "secId": "s0075",
            "sentence": "However, the need for vaccinating infants, the age at vaccination and the number of administered doses should be dictated by geographic and epidemiological factors.",
            "startOffset": 46298,
            "title": "Conclusions"
        },
        {
            "endOffset": 29550,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study is registered at www.clinicaltrials.gov (NCT01340898) and a protocol summary is available at http://www.gsk-clinicalstudyregister.com/114858.",
            "startOffset": 29399,
            "title": "Study design and participants"
        },
        {
            "endOffset": 46689,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Conclusions"
                }
            ],
            "secId": "s0080",
            "sentence": "Nimenrix is a trademark of the GSK group of companies, licensed to Pfizer.",
            "startOffset": 46615,
            "title": "Trademark statement"
        },
        {
            "endOffset": 36951,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Post-booster vaccination, higher anti-TT antibody GMCs were observed in group ACWY1 than in groups ACWY3+1 and ACWY1+1 (Table 3).",
            "startOffset": 36822,
            "title": "Immune responses to co-administered vaccines"
        },
        {
            "endOffset": 25228,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 25174,
                    "startOffset": 25171
                }
            },
            "secId": "s0005",
            "sentence": "IMD is caused by different serogroups of Neisseria meningitidis, 6 of those (MenA, MenB, MenC, MenW, MenX and MenY) being responsible for the majority of IMD cases [1], although epidemiology varies greatly geographically.",
            "startOffset": 25007,
            "title": "Introduction"
        },
        {
            "endOffset": 26559,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 26558,
                    "startOffset": 26551
                },
                "b0070": {
                    "endOffset": 26558,
                    "startOffset": 26551
                },
                "b0075": {
                    "endOffset": 26558,
                    "startOffset": 26551
                }
            },
            "secId": "s0005",
            "sentence": "MenACWY-TT was first licensed in 2012 in Europe and Canada for individuals \u22652 years of age followed by an extension of its indication as of 6 weeks of age in Europe [13\u201315].",
            "startOffset": 26386,
            "title": "Introduction"
        },
        {
            "endOffset": 44138,
            "parents": [],
            "secId": "s0070",
            "sentence": "The 3+1 schedule would ensure immunization against IMD from an early age, while the 1+1 schedule might be used to offer a similar level of protection in children not likely to be exposed to IMD in the first 6 months of life.",
            "startOffset": 43914,
            "title": "Discussion"
        },
        {
            "endOffset": 34941,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "For each serogroup, rSBA booster responses were observed for \u226590.2% and \u226582.4% of participants in groups ACWY3+1 and ACWY1+1, respectively.",
            "startOffset": 34802,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 47269,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Conclusions"
                }
            ],
            "secId": "s0085",
            "sentence": "GD and JCFT were the principal investigators at the participating sites, responsible for the administrative, logistic and technical support, the recruitment and the medical evaluation of subjects, the collection of data and the conduct of the study and participated in the analysis of the data.",
            "startOffset": 46975,
            "title": "Authors\u2019 contribution"
        },
        {
            "endOffset": 38181,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "For all groups and timepoints, grade 3 and vaccination-related unsolicited AEs were reported after \u22647.0% and \u22643.5% of doses, respectively (Table S4).",
            "startOffset": 38032,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 38494,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "At least one SAE was reported for 9.3% of participants in group ACWY3+1, and 7.5% of participants in each of the ACWY1+1 and ACWY1 groups.",
            "startOffset": 38356,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 38739,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "No infections due to pathogens targeted by MenACWY-TT or co-administered vaccines were reported throughout the study.",
            "startOffset": 38622,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 46103,
            "parents": [],
            "secId": "s0075",
            "sentence": "Co-administration of MenACWY-TT with DTPa-IPV/Hib and PHiD-CV during the first years of life was immunogenic, well-tolerated and no safety concerns were identified.",
            "startOffset": 45939,
            "title": "Conclusions"
        },
        {
            "endOffset": 44967,
            "parents": [],
            "secId": "s0070",
            "sentence": "When assessing immune responses to PHiD-CV, no functional assay testing was done, due to the limited volume of sera available.",
            "startOffset": 44841,
            "title": "Discussion"
        },
        {
            "endOffset": 27587,
            "parents": [],
            "secId": "s0005",
            "sentence": "This study also evaluates a 1+1 schedule, as well as a single dose in toddlers.",
            "startOffset": 27508,
            "title": "Introduction"
        },
        {
            "endOffset": 36741,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "The proportion of participants with pneumococcal antibody concentrations \u2265 0.35 \u03bcg/mL for each of the PHiD-CV vaccine serotypes was 75.2\u201387.3% and 76.7\u201389.7% after primary and booster vaccination, respectively (Table 3); Table S3 presents results for the 0.15 \u03bcg/mL threshold.",
            "startOffset": 36465,
            "title": "Immune responses to co-administered vaccines"
        },
        {
            "endOffset": 40502,
            "parents": [],
            "secId": "s0070",
            "sentence": "A more pronounced effect of cumulative doses was observed for hSBA GMTs, with increasing GMTs with the number of primary doses received.",
            "startOffset": 40366,
            "title": "Discussion"
        },
        {
            "endOffset": 26053,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 25974,
                    "startOffset": 25970
                },
                "b0055": {
                    "endOffset": 26052,
                    "startOffset": 26048
                }
            },
            "secId": "s0005",
            "sentence": "While treatment of IMD may be complex, with the choice of antibiotics depending on age and local resistance rates [10], the disease is preventable and several vaccines are currently available [11].",
            "startOffset": 25856,
            "title": "Introduction"
        },
        {
            "endOffset": 46297,
            "parents": [],
            "secId": "s0075",
            "sentence": "Our results support the potential use of MenACWY-TT in routine pediatric vaccination programs worldwide to ensure protection against IMD caused by 4 meningococcal serogroups at a very young age.",
            "startOffset": 46103,
            "title": "Conclusions"
        },
        {
            "endOffset": 33917,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "One month post-primary vaccination, in the ACWY3+1 group, the LL of the 95% CI for the percentage of infants with rSBA titers \u22658 was \u226597.8%, for each serogroup (Table 1).",
            "startOffset": 33747,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 28622,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Text S1 presents full inclusion/exclusion criteria.",
            "startOffset": 28571,
            "title": "Study design and participants"
        },
        {
            "endOffset": 44473,
            "parents": [],
            "secId": "s0070",
            "sentence": "The study had several potential limitations.",
            "startOffset": 44429,
            "title": "Discussion"
        },
        {
            "endOffset": 43058,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 43057,
                    "startOffset": 43054
                }
            },
            "secId": "s0070",
            "sentence": "MenA is the major cause of disease in the Middle East and North Africa, while outbreaks due to MenW were also recorded [2].",
            "startOffset": 42935,
            "title": "Discussion"
        },
        {
            "endOffset": 35952,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "In exploratory analyses, higher rSBA GMTs for MenC were observed in group ACWY3+1 compared to ACWY1+1, post-primary vaccination.",
            "startOffset": 35824,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 44332,
            "parents": [],
            "secId": "s0070",
            "sentence": "Our trial was designed with sufficient power to assess the primary confirmatory objective, and with a non-inferiority criterion that complied with guidelines imposed by regulatory organizations.",
            "startOffset": 44138,
            "title": "Discussion"
        },
        {
            "endOffset": 42197,
            "parents": [],
            "secId": "s0070",
            "sentence": "The reactogenicity profile of MenACWY-TT was similar between groups.",
            "startOffset": 42129,
            "title": "Discussion"
        },
        {
            "endOffset": 33696,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Demographic characteristics were balanced between groups (Table S2).",
            "startOffset": 33628,
            "title": "Demographics"
        },
        {
            "endOffset": 40715,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 40686,
                    "startOffset": 40682
                },
                "b0130": {
                    "endOffset": 40707,
                    "startOffset": 40703
                }
            },
            "secId": "s0070",
            "sentence": "Intriguingly, MenC rSBA GMTs were lower compared to other serogroups in the ACWY1 group, an observation that was made in other studies, after a single dose of MenACWY-TT at 12\u201315 [25] or 12\u201323 months [26] of age.",
            "startOffset": 40503,
            "title": "Discussion"
        },
        {
            "endOffset": 41076,
            "parents": [],
            "secId": "s0070",
            "sentence": "Immunogenicity of DTP/IPV components was not impacted by its co-administration with MenACWY-TT, as evidenced by the high seroprotection/seropositivity rates.",
            "startOffset": 40919,
            "title": "Discussion"
        },
        {
            "endOffset": 33967,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Thus, the primary confirmatory objective was met.",
            "startOffset": 33918,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 41794,
            "parents": [],
            "refoffsets": {
                "b0140": {
                    "endOffset": 41793,
                    "startOffset": 41789
                }
            },
            "secId": "s0070",
            "sentence": "The effect of high anti-TT antibody levels due to conjugated meningococcal vaccines on the immune response to subsequent TT administration was discussed by others, noting a potential negative impact on tetanus immunity [28].",
            "startOffset": 41570,
            "title": "Discussion"
        },
        {
            "endOffset": 42698,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 42697,
                    "startOffset": 42693
                }
            },
            "secId": "s0070",
            "sentence": "Moreover, safety results in our study are also similar to those for separate administration of MenACWY-TT in infants and toddlers [14].",
            "startOffset": 42563,
            "title": "Discussion"
        },
        {
            "endOffset": 32297,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Analyses were performed separately for the primary and booster phases.",
            "startOffset": 32227,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 37611,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "In the booster phase, pain was also most frequently reported following vaccination, in 33.1%, 38.2% and 37.7% (MenACWY-TT), 38.3%, 40.6% and 43.1% (PHiD-CV), and 40.2%, 41.8% and 41.3% (DTPa-IPV/Hib) of participants in groups ACWY3+1, ACWY1+1, and ACWY1, respectively (Fig. 3).",
            "startOffset": 37334,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 45105,
            "parents": [],
            "secId": "s0070",
            "sentence": "The study was not designed to include a long-term follow-up to evaluate the persistence of the immune response to MenACWY-TT vaccination.",
            "startOffset": 44968,
            "title": "Discussion"
        },
        {
            "endOffset": 36464,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Post-primary vaccination, all children in the corresponding ATP subsets had antibodies concentrations/titers against DTP/IPV antigens above pre-specified thresholds (Table 3).",
            "startOffset": 36289,
            "title": "Immune responses to co-administered vaccines"
        },
        {
            "endOffset": 32227,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The power to meet the primary confirmatory objective was 99.4%, computed by assuming 90% of evaluable infants will have post-primary vaccination rSBA titers \u22658 for each serogroup.",
            "startOffset": 32048,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 40919,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 40918,
                    "startOffset": 40911
                },
                "b0065": {
                    "endOffset": 40918,
                    "startOffset": 40911
                },
                "b0070": {
                    "endOffset": 40918,
                    "startOffset": 40911
                },
                "b0075": {
                    "endOffset": 40918,
                    "startOffset": 40911
                }
            },
            "secId": "s0070",
            "sentence": "Immune responses to MenACWY-TT vaccination within the same group were similar between countries, as expected from previous data obtained in different geographic locations in infants and toddlers [12\u201315].",
            "startOffset": 40716,
            "title": "Discussion"
        },
        {
            "endOffset": 34693,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Post-booster vaccination, GMTs for each serogroup increased \u2265 33.3- and \u2265 22.0-fold from pre-booster levels in groups ACWY3+1 and ACWY1+1, respectively.",
            "startOffset": 34541,
            "title": "Immune response to MenACWY-TT"
        },
        {
            "endOffset": 34540,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                },
                {
                    "id": "s0050",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0055",
            "sentence": "Post-primary rSBA GMTs s ranged from 577.5 (MenA) to 1190.3 (MenW) in group ACWY3+1 and from 591.6 (MenC) to 1469.9 (MenY) in group ACWY1+1 (Fig. 2A).",
            "startOffset": 34390,
            "title": "Immune response to MenACWY-TT"
        }
    ],
    "docId": "S0264410X18306662",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "gdbaibo@aub.edu.lb",
                "first": "Ghassan",
                "initial": "G.",
                "last": "Dbaibo"
            },
            {
                "email": "jctinoco@prodigy.net.mx",
                "first": "Juan Carlos",
                "initial": "J.C.",
                "last": "Tinoco Favila"
            },
            {
                "email": "magali.x.traskine@gsk.com",
                "first": "Magali",
                "initial": "M.",
                "last": "Traskine"
            },
            {
                "email": "archana.m.jastorff@gsk.com",
                "first": "Archana",
                "initial": "A.",
                "last": "Jastorff"
            },
            {
                "email": "marie.x.van-der-wielen@gsk.com",
                "first": "Marie",
                "initial": "M.",
                "last": "Van der Wielen"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.05.046",
        "firstpage": "4102",
        "issn": "0264410X",
        "keywords": [
            "Booster",
            "Co-administration",
            "Immunogenicity",
            "Infants",
            "Quadrivalent meningococcal conjugate vaccine"
        ],
        "lastpage": "4111",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study"
    }
}